- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07836478
Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)
Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.
Přehled studie
Postavení
Podmínky
Detailní popis
In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.
Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.
The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.
The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.
From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.
Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Gabriella Pravettoni
- Telefonní číslo: +39 0257489207
- E-mail: Gabriella.Pravettoni@ieo.it
Studijní místa
-
-
Italy
-
Milan, Italy, Itálie, 20141
- European Institute of Oncology, Milan
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment
Popis
Inclusion Criteria:
- Primary tumors of Brain Tumor (CNS), benign and malignant
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
- Radiological diagnosis, biopsy, or previous surgery
- Concomitant medical therapy is allowed
Exclusion Criteria:
- Previous brain radiotherapy (any form)
- High-grade gliomas
- Patients with concomitant neurological or psychiatric disorders.
- Pregnancy
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The presence of cognitive impairment
Časové okno: From the end of Protontherapy through study completion, an average of 1 year.
|
The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment. |
From the end of Protontherapy through study completion, an average of 1 year.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Perceived cognitive impairment
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Depressive symptoms
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Anxiety
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For EORTC QLQ C30, 30 items will be completed (score 1-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Sleep quality
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Cognitive Reserve
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Global functioning
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Learning and Verbal Memory
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Working memory
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Corsi Span backward/forward 18 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visual memory
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visuospatial abilities
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Executive function
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Attention
Časové okno: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- UID 5445
- L2-684 (Jiný identifikátor: Comitato Etico Lombardia 2)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .